Elevated blood glucose after compound 48/80 treatment is not related to hepatic mast cell degranulation in rats.
Blood glucose, hepatic glycogen, and the histological integrity of hepatic mast cells, were evaluated in anesthetized rats receiving iv injections of 0.125 mg/kg body weight compound 48/80 (a mast cell degranulator) and/or of 0.001 to 10.0 mg/kg body weight lodoxamide tromethamine (an inhibitor of mast cell degranulation). A nonglucogenic dose of lodoxamide, 0.001 mg/kg body weight, prevented dissipation of histochemically demonstrable fluorescence in mast cells (degranulation) without inhibiting compound 48/80-induced hyperglycemia and hepatic glycogenolysis. These results suggest that this glucotropic response is independent of compound 48/80-evoked release of mediators such as serotonin from mast cells.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003594:Cytoplasmic Granules / Q000187:drug effects; D008099:Liver / Q000166:cytology*; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D008407:Mast Cells / Q000166:cytology*; D009570:Nitriles; D010072:Oxamic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014325:Tromethamine / Q000031:analogs & derivatives / Q000494:pharmacology; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology*
D001786:Blood Glucose; D008112:Liver Glycogen; D009570:Nitriles; D014325:Tromethamine; D003189:p-Methoxy-N-methylphenethylamine; C022028:lodoxamide tromethamine; D010072:Oxamic Acid